SUMMARY

• The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
• Patients with guttate psoriasis were excluded from multicenter, randomized, double-blind trials assessing the safety and efficacy of TREMFYA in subjects with moderate to severe plaque psoriasis who were eligible for systemic therapy or phototherapy.^1-3
• Case reports describing the use of TREMFYA in patients with guttate psoriasis are outlined below.^4-6

Clinical Data

Case Reports

Abbad-Jaime de Aragón et al (2024)⁴ described the case of a 33-year-old male patient with guttate psoriasis that resolved after 2 doses of TREMFYA.

• The patient presented with a 4-week history of small, drop-like, erythematous papules/plaques on the trunk.
• Prior to the onset of guttate psoriasis, the patient had a 7-month history of scalp psoriasis that was treated with topical corticosteroids without any improvement.
• The patient was administered TREMFYA 100 mg subcutaneously at weeks 0 and 4. By week 8, there was complete resolution of lesions with no recurrence of psoriasis after 12 months of follow-up.

Bartholomew et al (2023)⁵ described the case of a 28-year-old female patient with guttate psoriasis that resolved completely after 6 doses of TREMFYA.

• During a telemedicine primary care visit, patient presented with a one-month history of small, raised, circular, pink-colored papules over the trunk and extremities. The onset of lesions occurred 1 week following a severe sunburn limited to the chest area, for which the patient was prescribed an unknown cream with no improvement.
• Subsequently, the patient visited a community dermatologist who confirmed the diagnosis of guttate psoriasis by performing a biopsy and prescribed topical clobetasol propionate 0.05%. However, the patient expressed difficulty adhering to the treatment due to numerous generalized spots and also experienced skin thinning on a few areas of the thighs after 3 months of using topical steroids without improvement.
• The patient presented to a dermatology clinic with multiple 2-4 mm, well-demarcated papules and small plaques with scale on the trunk and upper and lower extremities, with a Psoriasis Area and Severity Index (PASI) score of 6.7.
• The patient had a physician global assessment (PGA, maximum score of 5) score of 3 (moderate to severe).
• The patient enrolled in a clinical trial investigating the effect of TREMFYA on guttate psoriasis. TREMFYA 100 mg was subcutaneously administered at weeks 0, 4, 12, 20, 28, and 36.
• One month after receiving the first dose of TREMFYA, the patient had a PASI score of 0.4 and PGA score of 1 (clear/minimal).
• Eight months after the last dose of TREMFYA, the patient experienced complete remission with a PASI score of 0 and PGA score of 0 (clear).

Hall et al (2019)⁶ described the case of a 20-year-old female patient with guttate psoriasis that resolved after a single administration of TREMFYA.

• The patient presented to the dermatology clinic with guttate papules on the trunk and extremities and plaque-like lesions on the upper abdomen covering approximately 5% of the body surface area.
• One month prior to developing the lesions, the patient had a streptococcal throat infection and tested negative for tuberculosis.
• Patient received TREMFYA 100 mg subcutaneously and after 10 weeks, there was 100% improvement of the lesions.
• Areas of residual hypopigmentation were present where some of the previous lesions had been located with no recurrence 6 months after the patient received TREMFYA.

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® databases (and/or other resources, including internal/external databases) was conducted on 02 May 2024.